Literature DB >> 35354921

Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective.

Yoshihiro Hayashi1, Yuka Harada1,2, Hironori Harada3.   

Abstract

RUNX1 is a critical transcription factor for the emergence of definitive hematopoiesis and the precise regulation of adult hematopoiesis. Dysregulation of its regulatory network causes aberrant hematopoiesis. Recurrent genetic alterations in RUNX1, including chromosomal translocations and mutations, have been identified in both inherited and sporadic diseases. Recent genomic studies have revealed a vast mutational landscape surrounding genetic alterations in RUNX1. Accumulating pieces of evidence also indicate the leukemogenic role of wild-type RUNX1 in certain situations. Based on these efforts, part of the molecular mechanisms of disease development as a consequence of dysregulated RUNX1-regulatory networks have become increasingly evident. This review highlights the recent advances in the field of RUNX1 research and discusses the critical roles of RUNX1 in hematopoiesis and the pathobiological function of its alterations in the context of disease, particularly myeloid neoplasms, and clonal hematopoiesis.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35354921     DOI: 10.1038/s41375-022-01548-7

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  141 in total

1.  Nomenclature for Runt-related (RUNX) proteins.

Authors:  Andre J van Wijnen; Gary S Stein; J Peter Gergen; Yoram Groner; Scott W Hiebert; Yoshiaki Ito; Paul Liu; James C Neil; Misao Ohki; Nancy Speck
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

2.  t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1.

Authors:  H Miyoshi; K Shimizu; T Kozu; N Maseki; Y Kaneko; M Ohki
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

3.  Expression of the human acute myeloid leukemia gene AML1 is regulated by two promoter regions.

Authors:  M C Ghozi; Y Bernstein; V Negreanu; D Levanon; Y Groner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

Review 4.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

5.  PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene.

Authors:  E Ogawa; M Maruyama; H Kagoshima; M Inuzuka; J Lu; M Satake; K Shigesada; Y Ito
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

6.  Isolation of PEBP2 alpha B cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1.

Authors:  S C Bae; Y Yamaguchi-Iwai; E Ogawa; M Maruyama; M Inuzuka; H Kagoshima; K Shigesada; M Satake; Y Ito
Journal:  Oncogene       Date:  1993-03       Impact factor: 9.867

Review 7.  Core binding factor at the crossroads: determining the fate of the HSC.

Authors:  Kevin A Link; Fu-Sheng Chou; James C Mulloy
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

8.  Sequence specificity of the core-binding factor.

Authors:  I N Melnikova; B E Crute; S Wang; N A Speck
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

Review 9.  RUNX1 Mutations in Inherited and Sporadic Leukemia.

Authors:  Dana C Bellissimo; Nancy A Speck
Journal:  Front Cell Dev Biol       Date:  2017-12-20

10.  The evolution of Runx genes I. A comparative study of sequences from phylogenetically diverse model organisms.

Authors:  Jessica Rennert; James A Coffman; Arcady R Mushegian; Anthony J Robertson
Journal:  BMC Evol Biol       Date:  2003-03-24       Impact factor: 3.260

View more
  3 in total

Review 1.  Beyond Pathogenic RUNX1 Germline Variants: The Spectrum of Somatic Alterations in RUNX1-Familial Platelet Disorder with Predisposition to Hematologic Malignancies.

Authors:  Alisa Förster; Melanie Decker; Brigitte Schlegelberger; Tim Ripperger
Journal:  Cancers (Basel)       Date:  2022-07-14       Impact factor: 6.575

Review 2.  Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms.

Authors:  Xavier Roussel; Francine Garnache Ottou; Florian Renosi
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

Review 3.  Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation.

Authors:  Takashi Toya; Hironori Harada; Yuka Harada; Noriko Doki
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.